Adaphostin
CAS: 241127-58-2
Rif. 3D-FA17222
1mg | Fuori produzione | ||
2mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione |
Informazioni sul prodotto
- 4-[[(2,5-Dihydroxyphenyl)methyl]amino]benzoic acid tricyclo[3.3.1.13,7]dec-1-yl esterNSC 680410
- Nsc-680410
- Tricyclo[3.3.1.1~3,7~]Dec-1-Yl 4-[(2,5-Dihydroxybenzyl)Amino]Benzoate
Adaphostin is a potential anticancer agent that has been shown to inhibit oxidative injury and induce apoptosis in k562 cells. It also inhibits the production of reactive oxygen species and alters iron homeostasis. Adaphostin has been shown to inhibit mitochondrial membrane potential, dna binding activity, enzyme activities, and cell proliferation in vitro. This drug also has synergistic effects with other anticancer drugs such as doxorubicin. Adaphostin has been found to be active against various carcinoma cell lines and resistant mutants of these cells. The structural analysis of adaphostin revealed that it is a novel compound with an aminothiazole core and a pyridine ring system with two heterocycles attached at the 3-position.